concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: a retrospective analysis of the correlation between radiotherapy-related factors and tumor response

نویسندگان

y.j. park department of radiation oncology, ansan hospital, korea university medical center, ansan, republic of korea

w.s. yoon department of radiation oncology, ansan hospital, korea university medical center, ansan, republic of korea

j.a. lee department of radiation oncology, ansan hospital, korea university medical center, ansan, republic of korea

n.k. lee department of radiation oncology, ansan hospital, korea university medical center, ansan, republic of korea

چکیده

background: to determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (nsclc) patients undergoing concurrent chemoradiotherapy. materials and methods: thirty one patients with iiia/iiib nsclc underwent chemoradiotherapy with a median dose of 63 gy. on our actual treatments, we made radiotherapy planning to cover the planning target volume (ptv) with 95% of the prescribed dose, and checked the second ct simulation when a cumulative dose was about 36 gy. for this study, each ptv of primary tumor was re-defined with even margins from the gross target volume (gtv), and the actual plan overlaid the re-defined ptv. the correlations between the tumor response rate during chemoradiotherapy and after chemoradiotherapy, and the dose distribution parameters (d95, v95, mean tumor dose and homogeneity index), total dose and gtv, were evaluated. results: median overall survival was 15.5 months and the two-year survival 42.3%. at first recurrence, radiation-field recurrence, distant metastases and simultaneous recurrence were developed in 35.5%, 41.9% and 9.7% of the cases, respectively. the dose distribution parameters were generally favorable and were not related with tumor response rate. the tumor response rate after chemoradiotherapy was correlated with the residual gtv at second simulation (γ=-0.627, p<0.001) and the tumor response rate during chemoradiotherapy (γ=0.541, p=0.003). conclusion: minimal correlation was found between the dose distribution parameters that were over the minimal dose requirement and tumor response in nsclc with concurrent chemoradiotherapy. the small residual volume during chemoradiotherapy could indicate good tumor response after chemoradiotherapy.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: a retrospective analysis of the correlation between radiotherapy-related factors and tumor response

Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...

متن کامل

Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience.

The aim of the study was to compare the survival impact of concurrent versus sequential treatment with radiotherapy and chemotherapy in inoperable stage III non-small cell lung cancer (NSCLC). 85 patients were randomly assigned to one of the two treatment groups. In the sequential group, 45 patients had previously received sequential chemotherapy with 4 cycles of carboplatine and etoposide foll...

متن کامل

Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies

Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from...

متن کامل

Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer

For patients with unresectable locally-advanced non-small cell lung cancer (LA-NSCLC), concurrent chemoradiotherapy improves overall survival as compared to sequential chemotherapy and radiation therapy, but is associated with higher rates of toxicities. Acute, clinically significant esophagitis or pneumonitis can occur in one in five patients. The risks of esophagitis and pneumonitis can impac...

متن کامل

Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

PURPOSE To evaluate the predictive value of the early response of (18)F-flurodeoxyglucose positron emission tomography (FDG PET) during concurrent chemoradiotherapy (CCRT) for locally advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS FDG PET was performed before and during CCRT for 13 NSCLC patients. Maximum standardized uptake value (SUVmax), mean standardized uptake value (...

متن کامل

Chemoradiotherapy alone or in combination with Endostar for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis

Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of radiation research

جلد ۱۳، شماره ۳، صفحات ۲۰۵-۲۱۲

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023